EN
Stem cell therapy in Germany with proven benefit means, above all, transplantation of blood-forming cells for blood diseases and licensed cell products such as CAR-T, given by university and large centres on strict indications. Everything else offered with stem cells in Germany — injections for arthrosis, back pain or “rejuvenation” — lacks convincing evidence.
Two very different things share the name “stem cell therapy”: a routine, tightly regulated method used in Germany for decades, and commercial offers that German regulators warn patients about. Know the difference before you pay. Below: what is proven, where the field is moving, what the law allows, where treatment is done and how to check an offer.
What Is Proven: Transplantation of Blood-Forming Stem Cells
Stem cells have one proven field in wide use: transplantation of blood-forming cells in blood and bone marrow diseases — leukaemias, lymphomas, myeloma, aplastic anaemia and some inherited disorders. The cells come from the patients themselves, returned after high-dose chemotherapy (autologous transplantation), or from a matched donor (allogeneic). It is heavy, risky treatment, prescribed not “for restoration” but on a haematologist’s strict indications; see bone marrow transplant in Germany.
The German transplant registry (DRST) cumulatively records more than 88,000 autologous and more than 70,000 allogeneic transplants, plus more than 3,600 CAR-T cell therapies. To perform allogeneic transplants in adults at all, a hospital must carry out at least 40 a year: the Federal Joint Committee (G-BA) set this minimum because infrequent practice is dangerous here.
Blood-forming stem cells are usually coaxed from the marrow into the blood by medication and collected by machine; less often, marrow is taken directly from the pelvic bone. Mesenchymal stem cells come from fat tissue or bone marrow; commercial clinics most often sell these. Embryonic stem cells are not used in treatment, for legal reasons explained below. See the National Cancer Institute’s guide to stem cell transplants.
CAR-T and Gene Editing: Where the Field Is Moving
The field is moving not towards cosmetic medicine but to where transplantation meets genetics. In CAR-T therapy the patient’s own immune cells are taken out, reprogrammed in the laboratory to recognise the tumour and returned; such products are registered for particular lymphomas, leukaemias and myeloma, usually after relapse or failed treatment. See CAR-T cell therapy in Germany.
In February 2024 the European Commission for the first time authorised a product made by CRISPR genome editing: the patient’s own bone marrow stem cells are altered to produce working haemoglobin again. It is approved for severe sickle cell disease and transfusion-dependent beta thalassaemia, from the age of 12. That is the real leading edge: narrow indications, years of clinical trials, regulatory authorisation, an enormous price and clear accountability if something goes wrong.
Joints, Backs, Rejuvenation: Where the Evidence Is Missing
There is no good evidence that cell injections help with arthrosis, back pain or ageing skin. “Autologous” and other cell preparations are widely sold for joints, the spine and the skin, but nothing convincing shows that they restore destroyed cartilage or replace an operation. “A complete absence of side effects” and “regeneration of damaged tissue” are advertising, not study results; the claim that centrifuging blood “destroys cancer cells” is medically wrong.
Regulators also warn of direct harm: the European Medicines Agency reports serious, sometimes fatal complications after unproven cell procedures, including infections, unwanted immune reactions, tumour formation, loss of vision and bleeding in the brain. Unregulated products face no mandatory checks of quality, composition or storage. Another loss is time in which proven treatment could have started.
Cell Products and the Law: What Is Allowed and What Is Not
Preparations made from living cells are advanced therapy medicinal products (ATMP), legal in the EU only if authorised, used in an authorised clinical trial or approved nationally for hospital use. The European Commission grants EU authorisation after an assessment coordinated by the European Medicines Agency; the Paul Ehrlich Institute, Germany’s competent authority, issues national approvals and monitors safety (see its questions and answers on ATMPs). In March 2025 the agency and national regulators warned that unauthorised cell and gene products were being promoted on websites and social media, often without evidence of efficacy or safety; the institute published the warning in Germany.
Deriving embryonic stem cells is prohibited in Germany by the Embryo Protection Act; existing cell lines may be imported and used only for research, with a permit. So there is no “embryonic stem cell clinic” in Germany. A separate article explains whether and when stem cell therapy is legal in Germany.
Where Stem Cell Treatment in Germany Is Carried Out and How to Tell an Honest Offer
Stem cell treatment in Germany — transplantation and cell therapy — is carried out by haematology, oncology and stem cell transplantation departments of university and large municipal hospitals, for example: the Department of Internal Medicine I (Haematology, Oncology and Stem Cell Transplantation) at University Hospital Freiburg, medical director Prof. Justus Duyster; the Department of Haematology, Oncology, Stem Cell Transplantation and Palliative Medicine at München Klinik Bogenhausen, head physician Prof. Tobias Herold; the 4th Medical Clinic (Haematology, Stem Cell Transplantation and Oncology) at Helios Klinikum Erfurt, head physician Prof. Sebastian Scholl; and the haematology and stem cell transplantation department at Helios Klinikum Berlin-Buch.
Regulators name the warning signs: an experimental method offered outside an authorised trial; no European or national authorisation; a cure for a serious disease promised without published data; a high price no insurer covers; information only on the seller’s website and social media, not in the medical literature. Anyone looking for the “best stem cell therapy in Germany” is better served by checks than by a ranking: for a blood disease, ask about the transplant centre, its annual volume and protocol; for cells “for arthrosis”, “for ageing” or “for everything at once”, ask for the authorisation number and the publications behind it. The absence of a clear answer is informative in itself.
Private cell therapy clinics differ from hospital transplant units; the page on stem cell clinics in Germany compares both. The sum depends on the treatment and appears only in the clinic’s written estimate; see stem cell therapy cost in Germany.
Frequently asked questions
Which diseases can be cured with stem cells?
Reliable evidence of benefit exists for blood and bone marrow diseases: leukaemias, lymphomas, myeloma, aplastic anaemia and some inherited blood disorders. There, stem cell transplantation is established, and CAR-T is also used for some lymphomas, leukaemias and myeloma. Even so, no one can promise a cure; the outcome depends on the diagnosis, the stage and earlier treatment. Apart from a few narrow indications, other uses remain research.
Do stem cells help with arthrosis and back pain?
There is no convincing evidence that they do. In studies of knee arthrosis, cell injections may have eased pain slightly for the first few months compared with dummy injections, but repair of cartilage has not been shown. For back pain the evidence is weaker still, and any injection into a joint carries a small risk of infection.
How does a transplant of the patient’s own cells differ from a donor transplant?
In an autologous transplant patients get back their own cells, collected before high-dose chemotherapy, so there is no rejection and usually fewer complications. In an allogeneic transplant the cells come from a matched related or unrelated donor; it is heavier and can cause graft-versus-host disease, but for some leukaemias and myelodysplastic syndrome it offers the best, sometimes the only, chance of a cure. A haematologist decides.
How AlenMed Arranges Treatment
AlenMed starts with the records: discharge letters, bone marrow results, histology, genetic tests of the disease, and previous treatment with its response. The company translates them for haematology and transplant departments; the centre replies whether a transplant or a cell therapy is indicated, and which. AlenMed does not arrange treatment for which a clinic cannot name an indication.
Then come the clinic’s written estimate in the patient’s name, the visa invitation, accommodation near the clinic for the long follow-up and a medical interpreter. AlenMed works with 86 partner hospitals in 38 cities and 345 doctors; the company office is in Munich.
This material is for information only; it is not an offer and does not replace a consultation with a doctor. Whether treatment is possible, what it involves and what it achieves is decided by a doctor after an in-person examination.